Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A phase II, open-label study to evaluate corrected QT interval effects of Trastuzumab-MCC-DM1 (T-DM1) in patients with HER2-positive recurrent locally advanced or metastatic breast cancer and to evaluate the safety and tolerability of combined T-DM1 and Pertuzumab in patients with early disease progression while receiving T-DM1 alone.
trastuzumab emtansine
TDM4688g
NCT00943670
locally advanced or metastatic breast cancer
Phase 2
 
January 2014

Powered by ideaPoint, Inc.